News
Pembrolizumab significantly reduced the risk of event free survival events by 30% compared with standard of care.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback